Plus Therapeutics, Inc. focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases.Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma.
